Author Archives: Marisa Wexler MS

Health Canada Giving Priority Review to Trikafta

Health Canada is reviewing an application that seeks the approval of Trikafta, a triple combination reported to treat 90% of all with cystic fibrosis (CF), or those with least one F508del mutation. The request from Trikafta’s developer, Vertex Pharmaceuticals, covers eligible patients ages 12 and older, and has been granted…

Potential Antibiotic Appears to Effectively Treat M. abscessus Infections

A newly developed antibiotic, called T405, appears to effectively kill Mycobacteroides abscessus, a difficult-to-treat bacteria that can cause serious infections in people with lung conditions like cystic fibrosis (CF). The antibiotic was described in the study “Development of a penem antibiotic against Mycobacteroides abscessus,” published in Communications…

BiomX Testing Potential Therapy for CF Lung Infections

BiomX has unveiled a platform designed for more rapid and efficient development of phage therapy, which the company is using to test potential treatments, including one for Pseudomonas aeruginosa infections in people with cystic fibrosis (CF). According to a press release, the company expects results of a proof-of-concept…

Featured Column

Words Between Worlds: Improving Cross-class Communication in Medical Spaces

A banner for Kate Delany's "Breathe and Believe" column that depicts a pair of lungs with flowers blossoming from them.
Columnist Kate Delany investigates how communication between patients, family members, and doctors is often shaped by class origins.

Read the Column

Your CF Community

Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.